Sanofi And Alfresa To Develop Sabril In Japan
This article was originally published in PharmAsia News
Executive Summary
Sanofi and Japanese distributor Alfresa Holdings Corp have signed an agreement to develop anti-seizure agent Sabril (vagabatrin) for infantile spasms in Japan.